Tumor-Targeted IL-12 (PDS01ADC) With Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Nonrandomized Phase II Trial
JCO Oncology Advances, 2026
Eade A., Smith E., Monge C., Hannah C., Skorupan N., Hrones D., Celades C., Goswami M., Bagheri H., Smith K., Rainey A., Friedman L., Larrain C., Pu T., Sinha S., Desai P., Remmert K., Satterwhite A., Joyce S., Dinerman A., Wood B., Kassin M., Ukeh I., Blakely A., Davis J., Kleiner D., Lassoued W., Gameiro S., Donahue R., Gulley J., Schlom J., Hernandez J.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Immunotherapy Oncolcogy | Pathophysiology | Plasma |  Olink Target 96 |
Abstract
PURPOSE
Most patients with metastatic colorectal cancer (CRC) have microsatellite stable or mismatch repair-proficient tumors, which are resistant to immunotherapy especially in cases of liver metastases. We sought to determine whether tumor-targeted interleukin-12 (PDS01ADC) can improve outcomes for patients with CRC liver metastases managed with hepatic artery infusion pump (HAIP) chemotherapy.
MATERIALS AND METHODS
NCT05286814 is a phase II nonrandomized trial evaluating subcutaneous PDS01ADC in combination with HAIP floxuridine and systemic chemotherapy (leucovorin, 5-fluorouracil, and oxaliplatin or leucovorin, 5-fluorouracil, and irinotecan) in patients with unresectable microsatellite stable or mismatch repair-proficient colorectal liver metastases previously treated with at least one line of systemic chemotherapy. The primary end points for the planned interim analysis were overall response rate and safety.
RESULTS
Nine patients were included in this planned interim analysis. Seventy-eight percent (7/9) of patients receiving PDS01ADC with HAIP therapy had partial or complete responses at 6 months. The median hepatic progression-free survival for patients receiving PDS01ADC + HAIP therapy was 12.7 months with a minimum follow-up of 13.1 months. Grade ≥3 toxicities occurred in 78% but were manageable and did not limit HAIP therapy. No patients developed a biliary stricture within 6 months of initiating treatment. Clinical responders to PDS01ADC demonstrated enhanced peripheral immune activation, including elevated levels of circulating T-cell subsets with stem-like features, and increased CD8 + T-cell:T regulatory cell ratio in tissue biopsies.
CONCLUSION
Addition of PDS01ADC is not detrimental to HAIP therapy and is associated with both systemic and intratumoral immune modulation. Initial results warrant continuation to full enrollment for further evaluation of clinical and scientific end points.